Clinical trials recruiting in Lancaster, Pennsylvania

Phase breakdown

Conditions recruiting in Lancaster, Pennsylvania

Recruiting trials in Lancaster, Pennsylvania

• A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
  NCT07190248 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
  NCT05489705 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
  NCT06992258 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
  NCT07567001 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
  NCT06345729 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
  NCT06362252 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
  NCT06952803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
  NCT07164443 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male
• A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
  NCT07174336 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
  NCT06312137 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
  NCT06561386 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
  NCT06065748 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
  NCT07361510 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Assessment of CCM in HF With Higher Ejection Fraction
  NCT05064709 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
  NCT06059638 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
  NCT07207811 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
  NCT06096844 · Phase: Phase 3 · Ages: 70 Years and older · Sex: All (male and female)
• Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
  NCT06122077 · Phase: Not specified · Ages: 50 Years and older · Sex: All (male and female)
• Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
  NCT05174169 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Comparing Direct vs Indirect Methods for Cascade Screening
  NCT05348564 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Dilated Cardiomyopathy Detection Using AI and Screening With Mobile Technology (DCM-DETECT)
  NCT06688396 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• E-Mindfulness Approaches for Living After Breast Cancer
  NCT06748222 · Phase: Phase 3 · Ages: 18 Years to 50 Years · Sex: All (male and female)
• ELEVATE-HFpEF Clinical Study
  NCT06678841 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years and older · Sex: All (male and female)
• Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
  NCT05879926 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: Female
• Foundational Programs to Combat Clinician Stress
  NCT07220421 · Phase: Not applicable (e.g. observational or device study) · Ages: 25 Years to 70 Years · Sex: All (male and female)
• Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
  NCT06909565 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female)
• LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
  NCT06632457 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
  NCT06632444 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Left vs Left Randomized Clinical Trial
  NCT05650658 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
  NCT06134232 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male
• Persona Revision Knee System Outcomes
  NCT04821154 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Pharmacogenetics of Response to GLP1R Agonists
  NCT05071898 · Phase: Phase 1 · Ages: 18 Years to 89 Years · Sex: All (male and female)
• Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
  NCT07291037 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
  NCT00271180 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female)
• Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias
  NCT04088071 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• Study of ORIC-944 in Patients With Metastatic Prostate Cancer
  NCT05413421 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male
• Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
  NCT07745361 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
  NCT05633654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
  NCT06559891 · Phase: Not applicable (e.g. observational or device study) · Ages: 22 Years to 75 Years · Sex: All (male and female)
• Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
  NCT05624996 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
  NCT05673148 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
  NCT06377852 · Phase: Phase 3 · Ages: 60 Years and older · Sex: All (male and female)
• The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
  NCT03142152 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female)
• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
  NCT07028853 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male

Common questions

How many clinical trials are recruiting in Lancaster, Pennsylvania?

44 recruiting trials have at least one study site in Lancaster, Pennsylvania.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.